Skip to main content

JHOP - December 2022 Vol 12, No 6

Peer Reviewers
Case Reports
Original Research
Review Article
FDA Updates
Peer Reviewers
Peer Reviewers
Thank You JHOP Peer Reviewers
Read More
Case Reports
Case Reports, Pancreatic Cancer, Chemotherapy, Adverse Events, Dose Escalation/Reduction
Neoadjuvant FOLFIRINOX Therapy for a Patient with Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Hemodialysis: Case Report
Mark E. Jao, PharmD; Kathyrn S. Lee, PharmD, BCOP; Shannon Jeong, PharmD; Reid Nakagawa, PharmD; Eve-Michelle Segal, PharmD, BCOP; Stacey Cohen, MD
Read More
Case Reports, Lung Cancer, Screening, Tyrosine Kinase Inhibitor
The Presence of De Novo EGFR T790M Mutation in a Tyrosine Kinase Inhibitor–Naïve Patient with Lung Adenocarcinoma: Case Report and Review of the Literature
Jessica Katiaj, PharmD; Rosemary Boshar, PharmD; Maryann R. Cooper, PharmD, BCOP; Gerald Gehr, MD
Read More
Original Research
Original Research, Adverse Events, Immunotherapy, Checkpoint Inhibitors
Incidence of Hypothyroidism in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Nada Alsuhebany, BSPharm, PharmD, BCOP; Anastasia Graham, PharmD, MBA, BCOP; Erin Weeda, PharmD, BCPS; Amy Sion, PharmD, BCOP
Read More
Original Research, Chemotherapy, Adverse Events, Oncology Pharmacy Programs/Protocols
Assessment of the Elimination of Test Doses for Paclitaxel and Carboplatin in Patients with Cancer
Colleen McCann, PharmD; Aaron Steele, PharmD, BCOP
Read More
Original Research, Adverse Events, PARP Inhibitors, Screening
Outcomes and Adverse Events Linked to Off-Label Treatment of Solid Tumors with PARP Inhibitors
Bestis Wasef, PharmD, BCOP; Kelly Fritz, PharmD, BCOP; Courtney C. Cavalieri, PharmD, BCOP
Read More
Review Article
Review Article, Pancreatic Cancer, Clinical Trials, Chemotherapy, Immunotherapy, Targeted Therapies
Pancreatic Cancer: Review of the Current and Investigational Drug Landscape
Kevin H. Pang, PharmD; Valassia Antigone Theocharides; Yuxi Lei; Shivani K. Rana, BS; Richa K. Rana, BS; Mark H. Mansour; Meghana K. Ganjam; Jennifer Ahmed, PharmD
Read More
FDA Updates
FDA Updates
Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer
Read More
FDA Updates
Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation
Read More
FDA Updates
Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma
Read More
FDA Updates
Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma
Read More
FDA Updates
Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer
Read More
FDA Updates
Rylaze Received FDA Approval of a New Dosing Regimen
Read More
FDA Updates
Adcetris plus Chemotherapy Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma
Read More
FDA Updates
Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations
Read More